key: cord-0785425-ur3qbq7t authors: Zhou, Hao; Dcosta, Belinda M.; Samanovic, Marie I.; Mulligan, Mark J.; Landau, Nathaniel R.; Tada, Takuya title: B.1.526 SARS-CoV-2 variants identified in New York City are neutralized by vaccine-elicited and therapeutic monoclonal antibodies date: 2021-03-24 journal: bioRxiv DOI: 10.1101/2021.03.24.436620 sha: 4ff58463d83d80c31cc95d2372c2b441c57061c7 doc_id: 785425 cord_uid: ur3qbq7t DNA sequence analysis recently identified the novel SARS-CoV-2 variant B.1.526 that is spreading at an alarming rate in the New York City area. Two versions of the variant were identified, both with the prevalent D614G mutation in the spike protein together with four novel point mutations and with an E484K or S477N mutation in the receptor binding domain, raising concerns of possible resistance to vaccine-elicited and therapeutic antibodies. We report that convalescent sera and vaccine-elicited antibodies retain full neutralizing titer against the S477N B.1.526 variant and neutralize the E484K version with a modest 3.5-fold decrease in titer as compared to D614G. The E484K version was neutralized with a 12-fold decrease in titer by the REGN10933 monoclonal antibody but the combination cocktail with REGN10987 was fully active. The findings suggest that current vaccines and therapeutic monoclonal antibodies will remain protective against the B.1.526 variants. The findings further support the value of wide-spread vaccination. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a highly transmissible and pathogenic coronavirus that became an ongoing pandemic late in 2019. Infection rates have begun to fall, at least in part, due to large-scale vaccination efforts. In addition, treatment of infected patients with monoclonal antibodies against the spike protein have been found to reduce hospitalization and mortality [1, 2] . The recent emergence of SARS-CoV-2 variants raises concerns both with regard to vaccine efficacy and the effectiveness of monoclonal antibody therapy. The vast majority of sequenced SARS-CoV-2 isolates contain a D614G mutation in the spike protein [3] that increases viral infectivity and transmissibility [4] [5] [6] and subsequently, variants with multiple mutations in the spike protein and enhanced transmissibility have emerged in the United Kingdom [7-9], South Africa [10] , Brazil [11] and the United States [12, 13] raising concerns of diminished neutralization by immune sera-elicited antibodies and escape from therapeutic monoclonal antibodies. Recent reports have identified a novel variant in New York City termed B.1.526 that was rapidly spreading [14] [15] [16] . The variant was identified in November, 2020; by January, 2021 the variant accounted for 5% of genomes sequenced from individuals in New York and by mid-February was detected with a frequency of 12.3% [14] [15] [16] . The variant contains several mutations in the spike protein, some of which have not been found in previous variants. Two versions of B.1.526 were identified; both with the D614G mutation and A701V, in addition, the mutations L5F, T95I and D253G which are not present in previously reported variants. One version of B.1.526 contains the E484K mutation which is present in the B.1.351 and B.1.1.248 variant spike proteins and allows for partial escape from immune sera neutralization [17] [18] [19] [20] [21] [22] [23] ; the other lacks the E484K mutation but has a nearby S477N mutation, which lies within the receptor binding domain (RBD) and thus may influence affinity for the entry receptor ACE2. The D253G mutation is located in the amino-terminal supersite that serves as a binding site for neutralizing antibodies while A701V is located adjacent to the furin processing site. The combination of mutations raises concerns that the B.1.526 variant might evade vaccine elicited and therapeutic antibodies. Previous studies have shown that the E484K in the B.1.351 spike protein leads to a degree of resistance to neutralization by both infection-and vaccine-elicited antibodies as well as to the REGN10933 therapeutic monoclonal antibody [24] [25] [26] [27] . Moreover, the B.1.351 variant spike protein has been found to reduce the level of protection provided by vaccination in populations in which the variant has become prevalent [24, 28] . In this study, we determined the susceptibility of the B.1.526 variants to neutralization by convalescent sera and sera from individuals vaccinated with the Pfizer BNT162b2 [29] and Moderna mRNA1273 vaccines [30] and by Regeneron therapeutic monoclonal antibodies [25, 31] . We found that the B.1.526 variant (S477N) was fully susceptible to neutralization while the B.1.526 with the E484K mutation neutralized with a modest (3.5fold) reduction in titer by convalescent and vaccine elicited antibodies. The B.1.526 spike proteins were readily neutralized by Regeneron antibody cocktail. The B.1.526 variant spike proteins contain the D614G mutation, a shared set of novel mutations (L5F, T95I, D253G, and A701V) and either E484K or S477N, both of which lie within the RBD (Fig. 1A and B) . To study the B.1.526 spike proteins, we constructed spike protein expression vectors for both B.1.526 versions and used these to produce lentiviral pseudotypes reporter viruses as previously described. Immunoblot analysis showed that both B.1.526 spike proteins were expressed and processed in transfected 293T cells and that both were incorporated into virions at a level comparable to that of the wild-type (D614G) spike protein (Fig. 1C) . The infectivity of B.1.526 variant pseudotypes on ACE2.293T was similar to that of wild-type (Fig. 1D) . To test the ability of convalescent sera to neutralize the B.1.526 viruses, we determined the neutralizing antibody titers of sera from individuals who had been infected prior to April 2020 on viruses with B.1.526, D614G and E484K spike proteins ( Fig. 2A) . The results showed that neutralizing titers against the S477N B.1.526 variant were similar to that of D614G while the neutralizing titers against the E484K B.1.526 variant decreased by 3.8-fold, a modest decrease that was attributed to the E484K mutation. To determine the ability of vaccine-elicited antibodies to neutralize the B. The recently identified B.1.526 variant SARS-CoV-2 appears to be increasing in prevalence in New York City raising concerns about reinfection and immunoevasion [14] [15] [16] . We report here that both S477N and E484K versions of B.1. All plasmid sequences were confirmed by DNA nucleotide sequencing. 293T cells were cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (P/S) at 37°C in 5% CO2. ACE2.293T is a clonal cell-line that stably expresses a transfected human ACE2. The cells were maintained in DMEM/1 µg/ml puromycin/10% FBS/1% P/S. Convalescent sera and sera from BNT162b2 or Moderna-vaccinated individuals were collected on day 28 following the second immunization at the NYU vaccine center with written consent under IRB approval (IRB 20-00595 and IRB 18-02037). Donor age and gender were not reported. Regeneron monoclonal antibodies (REGN10933 and REGN10987) were prepared as previously described [36] . SARS-CoV-2 spike-pseudotyped lentiviruses were produced by co-transfection of 293T cells with pMDL, pLenti.GFP-NLuc, pcCoV2.S-D19 (or variant spikes) and pRSV.Rev, as previously described [35] . The viruses were concentrated by ultracentrifugation and normalized by reverse transcriptase RT activity. To quantify neutralizing antibody, sera were serially diluted 2-fold and then incubated with pseudotyped virus (approximately 2.5 X 10 7 cps) for 30 minutes at room temperature. The mixture was then added to 1 X 10 4 ACE2.293T cells, corresponding to an MOI of 0.2 in a 96-well cell culture dish. After 2 days, luciferase activity was measured using Nano-Glo luciferase substrate (Nanolight). Luminescence was read in an Envision 2103 microplate luminometer (PerkinElmer). Cells were lysed in buffer containing 50 mM HEPES, 150 mM KCl, 2 mM EDTA, 0.5% NP-40, and protease inhibitor cocktail. Lysates (40µg) were separated by SDS-PAGE and transferred to a polyvinylidene difluoride membrane. The membranes were probed with anti-spike mAb (1A9) (GeneTex), anti-p24 mAb (AG3.0) and anti-GAPDH mAb (Life Technologies) followed by goat anti-mouse HRP-conjugated second antibody (Sigma). The blots were visualized with luminescent substrate (Millipore) and quantified on an iBright CL1000 Imager. All experiments were performed in technical duplicates or triplicates and data were analyzed using GraphPad Prism 8. Statistical significance was determined by the twotailed, unpaired t-test. Significance was based on two-sided testing and attributed to p< Starr TN, Greaney Neutralizing Antibody Cocktail, in Outpatients with Covid-19 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 Evolutionary and structural analyses of SARS-CoV-2 D614G spike protein mutation now documented worldwide The D614G mutation in SARS-CoV-2 Spike increases transduction of multiple human cell types The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity spike mutation increases entry efficiency with enhanced ACE2-binding affinity Estimated transmissibility and severity of novel SARS-CoV-2 Variant of Concern 202012/01 in England. CMMID Repository Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings Distinct Patterns of Emergence of SARS-CoV-2 Spike Variants including N501Y in Clinical Samples in Emergence in late 2020 of multiple lineages of SARS-CoV-2 Spike protein variants affecting amino acid position 677 SARS-CoV-2 lineage B New York region detected by software utility created to query the spike mutational landscape A Novel SARS-CoV-2 Variant of Concern, B.1.526, Identified in New York The localized rise of a B.1.526 SARS-CoV-2 variant containing an E484K mutation in New York State mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccineelicited sera Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine The work was funded by grants from the NIH to N. The authors declare no competing interests.